April 15th 2025
During a live event, Matthew Galsky, MD, discussed adjuvant nivolumab in muscle-invasive bladder cancer and the benefit in patients with high PD-L1.
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
42nd Annual CFS: Chemotherapy Foundation Symposium®: Innovative Cancer Therapy for Tomorrow
View More
Current Standard-of-Care Treatment for Patients With BCG-Unresponsive High-Risk NMIBC
November 30th 2023BCG-unresponsive NMIBC treatment aims to eradicate disease or prolong disease-free intervals, with radical cystectomy as gold standard; newer options like pembrolizumab and gemcitabine/docetaxel provide improved alternatives, though logistic challenges remain.
Watch
NFBISI-18 Questionnaire Provides QOL Insights in Urothelial Carcinoma
November 13th 2023An analysis, based on data from the JAVELIN 100 Bladder trial, found the NCCN/FACT Bladder Symptom Index-18 for assessing quality-of-life in patients with advanced urothelial carcinoma to be reliable and valid.
Read More
EV-302: Impact of Enfortumab Vedotin + Pembrolizumab in Metastatic Bladder Cancer
November 7th 2023Shifting their focus to metastatic bladder cancer, the Oncology Brothers and Rana McKay, MD, reflect on data from EV-302 and consider how enfortumab vedotin + pembrolizumab has shifted the treatment landscape.
Watch
SunRISe-1: Updated Data With TAR-200 Monotherapy in NMIBC
November 7th 2023Key opinion leader Rana McKay, MD, joins the Oncology Brothers Rahul Gosain, MD, and Rohit Gosain, MD, to review updated data in GU cancer from ESMO 2023, starting with TAR-200 monotherapy in patients with NMIBC and the SunRISE-1 trial.
Watch
Treatment Selection and Dosing Strategies Based on Trial Data in RCC
November 1st 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Benjamin Garmezy, MD, and participants discussed their takeaways from the phase 3 trials of immunotherapy and tyrosine kinase inhibitors in frontline renal cell carcinoma. This is the second article based on this event.
Read More
Future Directions in Urothelial Cancer Treatment: Clinical Trials and Novel Agents
September 21st 2023Arlene Siefker-Radtke, MD, highlights the ongoing quest for improved treatment options in metastatic urothelial cancer, emphasizing the role of clinical trials and novel agents in addressing unmet needs.
Watch
Second-Line Strategies in Metastatic Urothelial Cancer: Balancing Options and Risks
September 21st 2023Arlene Siefker-Radtke, MD, delves into the complexities of managing progressive disease in metastatic urothelial cancer, outlining considerations for immune checkpoint inhibitors, antibody drug conjugates, and other targeted therapies.
Watch
Frontline Options for Metastatic Urothelial Cancer: Tailoring Treatment Choices
September 21st 2023Diverse approaches to frontline treatment for metastatic urothelial cancer, including eligibility for cisplatin-based chemotherapy, alternative regimens, and the impact of drug shortages on treatment decisions.
Watch
Early Mutation Profiling in Urothelial Cancer: A Path to Targeted Therapy
September 21st 2023Arlene Siefker-Radtke, MD, emphasizes the importance of early mutation profiling in metastatic urothelial cancer and highlights the potential for targeted agents and clinical trials to improve treatment outcomes.
Watch
Biomarker Testing in Urothelial Cancer: Implications for Treatment Decisions
September 21st 2023The evolving role of biomarker testing, including PD-L1 expression and mutations like FGFR3, in guiding treatment decisions for urothelial cancer patients, shedding light on their clinical significance and potential impact on therapeutic choices.
Watch
Challenges in Treating Metastatic Urothelial Cancer: A Geriatric Perspective
September 21st 2023Expert insight into the complexities of managing metastatic urothelial cancer in geriatric patients with comorbidities, highlighting the importance of aggressive therapy in improving survival outcomes.
Watch
TALAPRO-2: First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer
July 13th 2023Toni Choueiri, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent updates from TALAPRO-2, which studied talazoparib plus enzalutamide in first-line metastatic castration-resistant prostate cancer.
Watch
Physicians Discuss Sequencing of Sacituzumab Govitecan in Bladder Cancer
July 12th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Pedro C. Barata, MD, MSc, and participants discussed when in sequence they would use sacituzumab govitecan for patients with metastatic urothelial cancer. This is the second of 2 articles based on this event.
Read More